MoleculeAI: Revolutionize your research with our in silico drug screening
Discover precise molecular targets quickly and cost-effectively, propelling your research forward.
Revolutionize your research with our in silico drug screening
Faced with the high cost and slow pace of in vitro and in vivo tests?
Our in silico solution accurately predicts molecular targets, speeding up your research process and significantly reducing costs.
Features
Specific Target Prediction.
Our advanced technology enables precise prediction
of molecular targets based on compound composition, even with minor variations.
This capability is crucial for the effective development of targeted treatments.
Novelty and Confidence Analysis.
Our tool categorizes target populations based
on novelty and confidence.
This includes known targets from literature, as well as
potential new targets, assessed with high levels of confidence or significant
novelty.
User-Friendly Interactive Reports.
Results are presented in user-friendly, interactive reports on a secure web interface, facilitating in-depth analysis and collaboration among peers and researchers.
Use cases
Biomedical processes altered by compound candidate
Compound’s target identification and ranking by novelty and confidence
Identification of mechanism of action of a candidate molecule
Benefits
✔Rapid service delivery
(1-7 days)
Get results fast with our quick turnaround time, ensuring that your research maintains momentum and stays on the cutting edge.
✔Up to 100-fold reduction in analysis time and cost.
Significantly reduce both the time and financial resources needed for complex biological data analysis, freeing up your budget and schedule for other critical research activities.
✔Advanced
Precision
Targeted predictions with confidence and novelty scores for each molecule.
Testimonials
"Strong prospective insight from identification of mechanism of action in Breast cancer progression"
E. B.
Research Director CNRS, France"Fresher and more powerfull than a chatGPT for health, far more advanced than the regular offer"
Undisclosed
Stakeholder, Mayo Clinic, USA"You are one of the very few that are working on something is of outmost importance: causality"
E.G.
Senior director, Artificial Intelligence Institute, France"Really cool work"
L.LD.
Senior Business Developper and serial entrepreneur, Serie B and IPO companies, USA"Really interesting approaches, totally in phase"
M.C.
MD, Professor and Director of Hospital and associate partner, International Clinical cluster"Happy to have found you"
B. B.
Pharm.D., Professor, France"Answering totally to an unmet need in medicine"
F.B.
MD, Professor, University Hospital, France"Super interesting and exciting"
MB. M.
MD, Professor, University Hospital, France"Intersting insights from complex experimental data"
J.P.
MD and CSO, Serie B Biotech company, Belgium"Exactly what we need"
A.BT.
CEO, Medtech company, France"We have to work together"
T.S.
CEO, Medtech company, France"Really powerfull for clinical trials and pivots"
D.P.
Business developper, Roche Diagnostics, France"Very interesting value proposition and offer, you should definitely push it forward"
Undisclosed
Stakeholder, European Space Agency"Very happy to work together"
P.K.
Professor, MIT fellow and Partner in Medtech multinational Serie B company"Very deep and exhaustive research information for our consortium"
O.S.
Senior Partner, PWC, Switzerland"Thank you a lot for your help, you saved us so much time!"
I.H.
Partner, PWC, Swirtzerland
FAQ - Questions/Answers
Our unique mix of deep learning and advanced analytics offers more accurate, faster, and cost-effective results.
Yes, our system is equipped to analyze from a single compound to hundreds efficiently.
Our platform is designed with a focus on user experience, making it accessible for all research levels.
Absolutely, our platform helps formulating hypotheses, especially in complex molecular studies.
Yes, our technology is versatile and can be tailored to various molecular research requirements.
